In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...
Schrödinger Inc.'s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said it has entered a multi-year collaboration agreement with Swiss pharma ...
Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...
Dublin is such a hub for big tech companies that you might think ‘if we come to Dublin, we’re going to be competing with all of them, we won't be able to get good staff’. But I think the opposite is ...
The EVOLVED trial found that early aortic valve intervention in patients with asymptomatic severe aortic stenosis (AS) and ...
“We are proud to help redefine CML treatment once again with Scemblix, as we continue to deliver on our 20+ year commitment to innovation and support in CML,” said Victor Bulto, President US, Novartis ...
We’re not done fighting here. And in fact The Video Game History Foundation, which worked together with the SPN on the proposed amendment, has issued a statement expressing pride in the work ...
The Drug Discovery Unit (DDU) initiated collaboration this summer on two projects with the Biomedical Research division of Novartis and is extremely proud ... Scott is funded by the Bill & Melinda ...
A rumor that food company Land O'Lakes had announced a return to its previous logo featuring a kneeling ... we need packaging that reflects the foundation and heart of our company culture ...
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies that have failed in their legal challenges to the Inflation Reduction Act. A ...
If approved, Kisqali could nearly double the number of patients eligible for CDK4/6 inhibitor adjuvant therapy,” said Patrick Horber M.D., President, International, Novartis. “Together with the recent ...